{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:05:43Z","timestamp":1778688343843,"version":"3.51.4"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,9,10]],"date-time":"2013-09-10T00:00:00Z","timestamp":1378771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,9,10]],"date-time":"2013-09-10T00:00:00Z","timestamp":1378771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Abbott Laboratories Ltd."},{"name":"AstraZeneca"},{"name":"Bristol-Myers Squibb"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck Serono"},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Takeda"},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]},{"name":"A subsidiary of Merck & Co., Inc."},{"name":"Whitehouse Station"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1111\/jcpt.12096","type":"journal-article","created":{"date-parts":[[2013,9,11]],"date-time":"2013-09-11T06:56:18Z","timestamp":1378882578000},"page":"528-532","source":"Crossref","is-referenced-by-count":12,"title":["A high incidence of exanthematous eruption associated with niacin\/laropiprant combination in Hong Kong Chinese patients"],"prefix":"10.1155","volume":"38","author":[{"given":"Y.-L.","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Medicine and Therapeutics; Prince of Wales Hospital; The Chinese University of Hong Kong; Shatin Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics; Prince of Wales Hospital; The Chinese University of Hong Kong; Shatin Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics; Prince of Wales Hospital; The Chinese University of Hong Kong; Shatin Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics; Prince of Wales Hospital; The Chinese University of Hong Kong; Shatin Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,9,10]]},"reference":[{"key":"10.1111\/jcpt.12096-BIB0001|jcpt12096-cit-0001","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12096-BIB0002|jcpt12096-cit-0002","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1111\/jcpt.12096-BIB0003|jcpt12096-cit-0003","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24\u00a0months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/jcpt.12096-BIB0004|jcpt12096-cit-0004","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12096-BIB0005|jcpt12096-cit-0005","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12096-BIB0006|jcpt12096-cit-0006","unstructured":"HPS2 THRIVE home page http:\/\/www.hps2-thrive.org"},{"key":"10.1111\/jcpt.12096-BIB0007|jcpt12096-cit-0007","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","author":"HPS2 THRIVE Collaborative Group","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1111\/jcpt.12096-BIB0008|jcpt12096-cit-0008","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12096-BIB0009|jcpt12096-cit-0009","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrendo.2012.22","article-title":"Niacin: another look at an underutilized lipid-lowering medication","volume":"8","author":"Creider","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1111\/jcpt.12096-BIB0010|jcpt12096-cit-0010","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/jcpt.12096-BIB0011|jcpt12096-cit-0011","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.amjcard.2012.05.009","article-title":"Effectiveness and safety of laropiprant on niacin-induced flushing","volume":"110","author":"Maccubbin","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1111\/jcpt.12096-BIB0012|jcpt12096-cit-0012","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1742-1241.2010.02620.x","article-title":"Extended-release niacin\/laropiprant lipid-altering consistency across patient subgroups","volume":"65","author":"Bays","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1111\/jcpt.12096-BIB0013|jcpt12096-cit-0013","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000228585","article-title":"Flushing profile of extended-release niacin\/laropiprant at initiation of therapy in Asian lipid clinic patients","volume":"114","author":"Kush","year":"2009","journal-title":"Cardiology"},{"key":"10.1111\/jcpt.12096-BIB0014|jcpt12096-cit-0014","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1185\/030079907X199637","article-title":"Validation of a questionnaire to assess niacin-induced cutaneous flushing","volume":"23","author":"Norquist","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/jcpt.12096-BIB0015|jcpt12096-cit-0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12096-BIB0016|jcpt12096-cit-0016","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMcp043986","article-title":"Clinical practice. Antibiotic allergy","volume":"354","author":"Gruchalla","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12096-BIB0017|jcpt12096-cit-0017","doi-asserted-by":"crossref","first-page":"134","DOI":"10.47102\/annals-acadmedsg.V41N3p134","article-title":"Bullous drug eruption secondary to nicotinic acid\/laropiprant","volume":"41","author":"Ho","year":"2012","journal-title":"Ann Acad Med Singapore"},{"key":"10.1111\/jcpt.12096-BIB0018|jcpt12096-cit-0018","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1124\/pr.110.003301","article-title":"International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B)","volume":"63","author":"Offermanns","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1111\/jcpt.12096-BIB0019|jcpt12096-cit-0019","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.pharmtox.48.113006.094746","article-title":"Nicotinic acid: pharmacological effects and mechanisms of action","volume":"48","author":"Gille","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"Suppl 1","key":"10.1111\/jcpt.12096-BIB0020|jcpt12096-cit-0020","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1038\/sj.bjp.0707488","article-title":"The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses","volume":"153","author":"Pettipher","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1111\/jcpt.12096-BIB0021|jcpt12096-cit-0021","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12096-BIB0022|jcpt12096-cit-0022","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/jcpt.12096-BIB0023|jcpt12096-cit-0023","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/pgs.12.108","article-title":"HLA and pharmacogenetics of drug hypersensitivity","volume":"13","author":"Pavlos","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jcpt.12096-BIB0024|jcpt12096-cit-0024","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","article-title":"Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong","volume":"167","author":"Chiu","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/jcpt.12096-BIB0025|jcpt12096-cit-0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000335613","article-title":"Genetics and the potential for predictive tests in adverse drug reactions","volume":"97","author":"Pirmohamed","year":"2012","journal-title":"Chem Immunol Allergy"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12096","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12096","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12096\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T13:29:53Z","timestamp":1688477393000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,10]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12096","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9,10]]}}}